Cognition Disorders Completed Phase 2 Trials for Selegiline (DB01037)

IndicationStatusPhase
DBCOND0027877 (Cognition Disorders)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00013585Safety and Effectiveness of the Selegiline "Patch" for Decreased Mental Function in HIV PatientsTreatment